Published in Gene Therapy Weekly, April 29th, 2004
Under the terms of the agreement, Xcellsyz will use hTERT to create immortalized cell lines for in-vitro use in drug discovery and screening. The license is limited to cell lines that also include a recombinant conditionally inducible oncogene, using Xcellsyz's own proprietary technology. In connection with the license, Geron will receive a license fee payment in cash and equity in Xcellsyz as well as royalties on future product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.